Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-20
2010-06-15
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252110, C514S253130, C514S254010, C514S255030, C544S121000, C544S357000, C544S360000, C544S372000, C544S393000
Reexamination Certificate
active
07737142
ABSTRACT:
The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I):wherein R1and R2represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R1and R2may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
REFERENCES:
patent: 6528529 (2003-03-01), Brann et al.
patent: 2003/0144285 (2003-07-01), Brann et al.
patent: WO-97/11070 (1997-03-01), None
patent: WO-99/50247 (1999-10-01), None
patent: WO-99/67206 (1999-12-01), None
patent: WO-01/05763 (2001-01-01), None
patent: WO-03/029233 (2003-04-01), None
Glase et al.; “4-Bromo-1-Methoxy-N-[2-(4-Aryl-1-Piperazinyl)Ethyl]-2- Naphthalenecarboxamides: Selective Dopamine D3Receptor Partial Agonists”; Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 12, pp. 1361-1366, Jun. 18, 1996.
International Search Report issued for International Application No. PCT/HU04/00056, date of mailing Nov. 11, 2004.
Belliotti et al., “Novel Cyclohexyl Amides as Potent and Selective D3Dopamine Receptor Ligands,” Bioorg. Med. Chem. Lett. 1997, 7, 18, 2403-2408.
Levant, “The D3Dopamine Receptor: Neurobiology and Potential Clinical Relevance,” Pharmacol. Rev. 1997, 49, 231-252.
Levant et al., “Dopamine D3Receptors: Relvance for the Drug Treatment of Parkinson's Disease,” CNS Drugs 1999, 12, 391-402.
Levant et al., “D3dopamine receptors in rat spinal cord: implications for sensory and motor function,” Neurosci. Lett. 2001, 303, 9-12.
Pilla et al., “Selective inhibition of cocaine-seeking behavior by a partial dopamine D3receptor agonist,” Nature 1999, 400, 371-375.
Schwartz et al., “Dopamine D3Receptor: Basic and Clinical Aspects,” Clin. Neuropharmacol. 1993, 16, 295-314.
Sokoloff et al., “Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics,” Nature , 1990, 347, 146-151.
Wong et al., “Schizophrenia: from phenomenology to neurobiology,” Neurosci. Biobehav. Rev. 2003, 27, 269-306.
Againe Csongor Eva
Galambos Janos
Gyertyan Istvan
Kiss Bela
Laszlovszky Istvan
Coleman Brenda L
Fish & Richardson P.C.
Richter Gedeon Vegyeszeti Gyar Rt.
LandOfFree
(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4208591